[1]
|
Holliger, P. and Hudson, P.J. (2005) Engineered antibody fragments and the rise of single domains. Nature Biotechnology, 23, 1126-1136. doi:10.1038/nbt1142
|
[2]
|
Buhler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W.W. and Elsasser-Beile, U. (2008) A bispecific diabody directed against prostatespecific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunology, Immunotherapy, 57, 43-52.
doi:10.1007/s00262-007-0348-6
|
[3]
|
Baeuerle, P.A. and Reinhardt, C. (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Research, 69, 4941-4944. doi:10.1158/0008-5472.CAN-09-0547
|
[4]
|
Thakur, A. and Lum, L.G. (2010) Cancer therapy with bispecific antibodies: Clinical experience. Current Opinion of Molecular Therapy, 12, 340-349.
|
[5]
|
Beckman, R.A., Weiner, L.M. and Davis, H.M. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer, 109, 170-179. doi:10.1002/cncr.22402
|
[6]
|
Toleikis, L. and Frenzel, A. (2012) Cloning single-chain antibody fragments (ScFv) from hyrbidoma cells. Methods of Molecular Biology, 907, 59-71.
|
[7]
|
Hoogenboom, H.R. (2005) Selecting and screening recombinant antibody libraries. Nature Biotechnology, 23, 11051116. doi:10.1038/nbt1126
|
[8]
|
Bradbury, A.R., Sidhu, S., Dübel, S. and McCafferty, J. (2011) Beyond natural antibodies: The power of in vitro display technologies. Nature Biotechnology, 29, 245-254.
doi:10.1038/nbt.1791
|
[9]
|
Amann, M., D’Argouges, S., Lorenczewski, G., Brischwein, K., Kischel, R., Lutterbuese, R., Mangold, S., Rau, D., Volkland, J., Pflanz, S., Raum, T., Munz, M., Kufer, P., Schlereth, B., Baeuerle, P.A. and Friedrich, M. (2009) Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. Journal of Immunotherapy, 32, 452-464.
doi:10.1097/CJI.0b013e3181a1c097
|
[10]
|
Asano, R., Kawaguchi, H., Watanabe, Y., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T. and Kumagai, I. (2008) Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. Journal of Immunotherapy, 31, 752-761.
doi:10.1097/CJI.0b013e3181849071
|
[11]
|
Buhler, P., Molnar, E., Dopfer, E.P., Wolf, P., Gierschner, D., Wetterauer, U., Schamel, W.W. and Elsasser-Beile, U. (2009) Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells. Journal of Therapy, 32, 565-573.
|
[12]
|
Kellner, C., Bruenke, J., Stieglmaier, J., Schwemmlein, M., Schwenkert, M., Singer, H., Mentz, K., Peipp, M., Lang, P., Oduncu, F., Stockmeyer, B. and Fey, G.H. (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. Journal of Immunotherapy, 31, 871884. doi:10.1097/CJI.0b013e318186c8b4
|
[13]
|
Lutterbuese, R., Raum, T., Kischel, R., Lutterbuese, P., Schlereth, B., Schaller, E., Mangold, S., Rau, D., Meier, P., Kiener, P.A., Mulgrew, K., Oberst, M.D., Hammond, S.A., Baeuerle, P.A. and Kufer, P. (2009) Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. Journal of Immunotherapy, 32, 341-352.
doi:10.1097/CJI.0b013e31819b7c70
|
[14]
|
Sebastian, M., Kiewe, P., Schuette, W., Brust, D., Peschel, C., Schneller, F., Ruhle, K.H., Nilius, G., Ewert, R., Lodziewski, S., Passlick, B., Sienel, W., Wiewrodt, R., Jager, M., Lindhofer, H., Friccius-Quecke, H. and Schmittel, A. (2009) Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (antiEpCAM x Anti-CD3): results of a phase 1/2 study. Journal of Immunotherapy, 32, 195-202.
doi:10.1097/CJI.0b013e318195b5bb
|
[15]
|
Xiong, D., Xu, Y., Liu, H., Peng, H., Shao, X., Lai, Z., Fan, D., Yang, M., Han, J., Xie, Y., Yang, C. and Zhu, Z. (2002) Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Letters, 1, 77, 29-39.
doi:10.1016/S0304-3835(01)00758-3
|
[16]
|
Jensen, M., Ernestus, K., Kemshead, J., Klehr, M., Von Bergwelt-Baildon, M.S., Schinkothe, T., Schultze, J.L. and Berthold, F. (2003) The bispecific CD3 x NCAM antibody: A model to preactivate T cells prior to tumour cell lysis. Clinical and Experimental Immunology, 134, 253-263. doi:10.1046/j.1365-2249.2003.02300.x
|
[17]
|
Grosse-Hovest, L., Brandl, M., Dohlsten, M., Kalland, T., Wilmanns, W. and Jung, G. (1999) Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T-cell costimulation via CD28. International Journal of Cancer, 80, 138-144.
doi:10.1002/(SICI)1097-0215(19990105)80:1<138::AID-IJC25>3.0.CO;2-J
|
[18]
|
Jung, G., Brandl, M., Eisner, W., Fraunberger, P., Reifenberger, G., Schlegel, U., Wiestler, O. and Wilmanns, W. (2001) Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ Tcell activation and therapeutic efficacy. International Journal of Cancer, 91, 225-230.
doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1038>3.3.CO;2-7
|
[19]
|
Chames, P. and Baty, D. (2009) Bispecific antibodies for cancer therapy: The light at the end of the tunnel? Mabs, 1, 539-547. doi:10.4161/mabs.1.6.10015
|
[20]
|
Verma, R., Boleti, E. and George, A.J. (1998) Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems. Journal of Immunological Methods, 216, 165-181.
doi:10.1016/S0022-1759(98)00077-5
|
[21]
|
Jostock, T. and Knopf, H.P. (2012) Mammalian stable expression of biotherapeutics. Methods in Molecular Biology, 899, 227-238.
doi:10.1007/978-1-61779-921-1_15
|
[22]
|
Young, C.L., Britton, Z.T. and Robinson, A.S. (2012) Recombinant protein expression and purification: A comprehensive review of affinity tags and microbial applications. Biotechnological Journal, 7, 620-634.
doi:10.1002/biot.201100155
|
[23]
|
Jensen, M. and Berthold, F. (2007) Targeting the neural cell adhesion molecule in cancer. Cancer Letters, 258, 921. doi:10.1016/j.canlet.2007.09.004
|
[24]
|
Spannuth, W.A., Nick, A.M., Jennings, N.B., ArmaizPena, G.N., Mangala, L.S., Danes, C.G., Lin, Y.G., Merritt, W.M., Thaker, P.H., Kamat, A.A., Han, L.Y., Tonra, J.R., Coleman, R.L., Ellis, L.M. and Sood, A.K. (2009) Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of Cancer, 124, 1045-1053.
doi:10.1002/ijc.24028
|
[25]
|
Rapisarda, A. and Melillo, G. (2012) Role of the VEGF/ VEGFR axis in cancer biology and therapy. Advanced Cancer Research, 114, 237-267.
|
[26]
|
Masood, R., Cai, J., Zheng, T., Smith, D.L., Hinton, D.R. and Gill, P.S. (2001) Vascular endothelial growth factor 8VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood, 98, 1904-1913.
doi:10.1182/blood.V98.6.1904
|
[27]
|
Böldicke, T., Tesar, M., Griesel, C., Rohde, M., Grone, H. J., Waltenberger, J., Kollet, O., Lapidot, T., Yayon, A. and Weich, H. (2001) Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/ flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem Cells, 19, 24-36. doi:10.1634/stemcells.19-1-24
|
[28]
|
Frankel, A.E., Zuckero, S.L., Mankin, A.A., Grable, M., Mitchell, K., Lee, Y.J., Neville, D.M. and Woo, J.H. (2009) Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Current Drug Targets, 10, 104-109. doi:10.2174/138945009787354539
|
[29]
|
Grosse-Hovest, L., Hartlapp, I., Marwan, W., Brem, G., Rammensee, H. and Jung, G. (2003) A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. European Journal of Immunology, 33, 1334-1340.
doi:10.1002/eji.200323322
|
[30]
|
Böldicke, T., Somplatzki, S., Sergeev, G. and Mueller, P. P. (2012) Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum. Methods, 56, 338-350.
doi:10.1016/j.ymeth.2011.10.008
|
[31]
|
Minsky, A., Summers, R.G. and Knowles, J.R. (1986) Secretion of beta-lactamase into the periplasm of Escherichia coli: Evidence for a distinct release step associated with a conformational change. Proceedings of National Academy Science of the USA, 83, 4180-4184.
doi:10.1073/pnas.83.12.4180
|
[32]
|
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. and Heldin, C. H. (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. Journal of Biological Chemistry, 269, 26988-26995.
|
[33]
|
Wigler, M., Sweet, R., Sim, G.K., Wold, B., Pellicer, A., Lacy, E., Maniatis, T., Silverstein, S. and Axel, R. (1979) Transformation of mammalian cells with genes from procaryotes and eucaryotes. Cell, 16, 777-785.
doi:10.1016/0092-8674(79)90093-X
|
[34]
|
Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J. and Klenk, D.C. (1985) Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76-85. doi:10.1016/0003-2697(85)90442-7
|
[35]
|
Burnette, W.N. (1981) “Western blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Analytical Biochemistry, 112, 195-203.
doi:10.1016/0003-2697(81)90281-5
|
[36]
|
Kung, P., Goldstein, G., Reinherz, E.L. and Schlossman, S.F. (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science, 206, 347-349.
doi:10.1126/science.314668
|
[37]
|
Bourne, S.P., Patel, K., Walsh, F., Popham, C.J., Coakham, H.B. and Kemshead, J.T. (1991) A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm. Journal of Neurooncology, 10, 111-119.
doi:10.1007/BF00146871
|
[38]
|
Whittington, H.A., Hancock, J. and Kemshead, J.T. (2001) Generation of a humanised single chain Fv (Scfv) derived from the monoclonal Eric-1 recognising the human neural cell adhesion molecule. Medical and Pediatric Oncology, 36, 243-246.
doi:10.1002/1096-911X(20010101)36:1<243::AID-MPO1060>3.0.CO;2-5
|
[39]
|
Pluckthun, A. (2012) Ribosome display: A perspective. Methods in Molecular Biology, 805, 3-28.
doi:10.1007/978-1-61779-379-0_1
|